Table 2 Summary of included studies on CPP throughout the COVID-19 pandemica
Author | Year | Country | AHRQ | N | Age | ||
|---|---|---|---|---|---|---|---|
Pre-pandemic | Pandemic | Pre-pandemic | Pandemic | ||||
Acinikli KY | 2022 | Turkey | 6 | 6 | 22 | 7.5 ± 1.0 | 7.5 ± 0.9 |
Chioma L | 2022 | Italy | 8 | 37 | 135 | 7.58 ± 0.94 | 7.39 ± 0.84 |
Umano GR | 2022 | Italy | 5 | 34 | 35 | 7.97 ± 1.11 | 7.59 ± 0.67 |
Trujillo MV | 2022 | USA | 5 | 28 | 64 | 7.1 ± 2.1 | 7.60 ± 1.43 |
Barberi C | 2022 | Italy | 5 | 9 | 17 | 7.27 ± 0.6 | 6.99 ± 1.38 |
Chen Y | 2022 | China | 4 | 209 | 191 | 7.92 ± 0.71 | 7.95 ± 0.57 |
Mondkar SA | 2023 | India | 5 | 44 | 136 | 7.8 ± 1.3 | 8.2 ± 1.2 |
Acar S | 2021 | Turkey | 6 | 25 | 58 | 7.9 ± 0.8 | 7.8 ± 0.8 |
Verzani M | 2021 | Italy | 5 | 93 | 224 | 7.54 ± 1.23 | 7.37 ± 8.79 |
Itani AA | 2022 | Lebanon | 4 | 4 | 19 | 6.66 ± 0.78 | 7.27 ± 0.73 |
Goffredo M | 2022 | Italy | 5 | 34 | 45 | / | / |
Orman B | 2022 | Turkey | 6 | 27 | 30 | / | / |
Mutlu GY | 2022 | Turkey | 7 | 214 | 145 | 8.6 ± 1.2 | 8.1 ± 8.1 |
Matsubara K | 2023 | Japan | 5 | 33 | 63 | / | / |
Stagi S | 2020 | Italy | 6 | 89 | 37 | 7.22 ± 0.48 | 6.86 ± 0.61 |